NCCN 13th Annual Congress:
Hematologic Malignancies™

EXHIBIT SCHEDULE

September 21 – 22, 2018
New York Marriott Marquis
1535 Broadway | New York, New York

- **Friday, September 21, 2018**
  Exhibits and Refreshments: 4:30 – 6:00 PM

- **Saturday, September 22, 2018**
  Exhibits: 7:00 AM – 3:55 PM

**NCCN Patient Advocacy Pavilions**
Visit patient advocacy kiosks representing a range of disease types; gather information on additional groups at the self-serve table tops.
Sponsored by: Johnson & Johnson Health Care Systems, Inc.; Sanofi-Genzyme; AbbVie, Inc.; and enterade®

**NCCN Exhibit # 11 & 26**
Stop by to receive a complimentary gift!

**NCCN Foundation Exhibit # 10 & 27**
Gather information on the latest patient resources.

**Complimentary Wi-Fi Access**
Sponsored by: Celgene Corporation; Incyte Corporation; Astellas; Jazz Pharmaceuticals, Inc.; Merck & Co., Inc.; Pharmacyclics LLC, an AbbVie Company; and Spectrum Pharmaceuticals, Inc.
Gold Level Sponsors

Celgene Corporation
Incyte Corporation

Bronze Level Sponsors

Astellas
Jazz Pharmaceuticals, Inc.
Merck & Co., Inc.
Pharmacyclics LLC, an AbbVie Company
Spectrum Pharmaceuticals, Inc.
Patient Advocacy Pavilion Sponsors

<table>
<thead>
<tr>
<th>Ruby</th>
<th>Johnson &amp; Johnson Health Care Systems, Inc.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Emerald</td>
<td>Sanofi-Genzyme</td>
</tr>
<tr>
<td>Topaz</td>
<td>AbbVie, Inc.</td>
</tr>
<tr>
<td></td>
<td>enterade®</td>
</tr>
</tbody>
</table>

REGISTER NOW

March 21 – 23, 2019
Rosen Shingle Creek
Orlando, FL

NCCN.org/conference

Sponsorship and exhibit opportunities available! For more information, e-mail: exhibits@nccn.org.

General Poster Session
Call for Abstracts!
Abstract Submission Deadline:
Wednesday, November 7, 2018
There’s more to uncover in FLT3m+ AML

Deepen your knowledge of FLT3m+ AML at

FLT3AML-revealed.com
Support your patients. Refer them to our INFORMATION SPECIALISTS

The Leukemia & Lymphoma Society’s Information Specialists are master’s level oncology social workers, nurses and health educators who are available by phone Monday through Friday, 9 a.m. to 9 p.m. (ET).

Patients will receive
- One-on-one personalized support and information about blood cancers
- Assistance in developing questions to ask their doctor
- Guidance regarding financial resources
- Individual clinical-trial searches

Patients can contact us at 800-955-4572 or www.LLS.org/InformationSpecialists (Language interpreters can be requested)
**EXHIBITOR** | **EXHIBIT #**
--- | ---
AbbVie | 19
Adaptive Biotechnologies | 35
Agios Pharmaceuticals | 15
Amgen, Inc. | 9
Astellas Pharma US, Inc. | 3
AstraZeneca | 22
Bayer Healthcare Pharmaceuticals, Inc. | 21
BMS/Pfizer | 28
Celgene Corporation | 1
Daichi Sankyo, Inc. | 25
enterade® | 36
Genentech | 6 & 7
Genoptix | 13
Gilead Sciences, Inc. | 32
Harborside | 12
Helsinn Therapeutics | 34
Incyte Corporation | 18
Janssen Oncology | 24
Jazz Pharmaceuticals, Inc. | 20
Karyopharm Therapeutics Inc. | 8
Kite, a Gilead Company | 31
Merck & Co., Inc. | 17
NCCN | 11 & 26
NCCN Foundation | 10 & 27
Novartis | 23
Pfizer | 5
Pharmacyclics, LLC | 2
Sandoz, a Novartis Division | 16
Seattle Genetics | 14
Servier Pharmaceuticals, Inc. | 30
Spectrum Pharmaceuticals, Inc. | 4
Takeda Oncology | 33
Verastem Oncology | 29

**PATIENT ADVOCATE** | **KIOSK #**
--- | ---
Cancer Hope Network | A1
CancerCare® | A2
CLL Society | A3
Lymphoma Research Foundation | A4
Myeloma Crowd | A5
New Tang Dynasty TV | A6
SHARE | A7
The Leukemia & Lymphoma Society | A8
About Our Exhibitors

AbbVie
Exhibit # 19

Our ~29,000 employees are scientists, researchers, communicators, manufacturing specialists and regulatory experts located around the globe. We come up with new approaches to addressing today’s health issues—from life-threatening illness to chronic conditions. We target specific difficult-to-cure diseases where we can leverage our core R&D expertise to advance science. We’re constantly working to create solutions that go beyond treating the illness to have a positive impact on patients’ lives, on societies—and on science itself. At AbbVie, we see a future full of possibility, where health is in reach and patient lives are improved.

Adaptive Biotechnologies
Exhibit # 35

Adaptive Biotechnologies is a pioneer and leader in combining NGS and expert bioinformatics to profile B- and T-cell receptors. Adaptive is bringing the accuracy and sensitivity of its immunosequencing platform to researchers and clinicians around the world to drive groundbreaking research in cancer and other immune-mediated diseases. Adaptive also translates immunosequencing discoveries into clinical diagnostics and therapeutic development to improve patient care. For more information, please visit adaptivebiotech.com.

Agios Pharmaceuticals
Exhibit # 15

Agios is focused on discovering and developing novel investigational medicines to treat cancer and rare genetic diseases through scientific leadership in the field of cellular metabolism. In addition to an active research and discovery pipeline across both therapeutic areas, Agios has an approved oncology precision medicine and multiple first-in-class investigational therapies in clinical and/or preclinical development. All Agios programs focus on genetically identified patient populations, leveraging our knowledge of metabolism, biology and genomics. For more information, please visit the company’s website at www.agios.com.

Amgen, Inc.
Exhibit # 9

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. A biotechnology pioneer since 1980, Amgen has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

Astellas Pharma US, Inc.
Exhibit # 3

Astellas Pharma US, Inc., is a U.S. affiliate of Tokyo-based Astellas Pharma Inc. Astellas is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. Astellas is committed to the areas of Oncology, Immunology, Infectious Disease, Cardiology, and Urology. To learn more about Astellas and the portfolio of products visit www.astellas.us.com

AstraZeneca
Exhibit # 22

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in three main therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit www.astrazeneca-us.com and follow us on Twitter @AstraZenecaUS.

Bayer Healthcare Pharmaceuticals, Inc.
Exhibit # 21

Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power.

BMS/Pfizer
Exhibit # 28

Pfizer and Bristol-Myers Squibb are partners in a worldwide collaboration. This global alliance combines both Bristol-Myers Squibb’s and Pfizer’s long-standing strengths in drug development and commercialization.

Celgene Corporation
Exhibit # 1

Celgene Corporation (Nasdaq:CELG) is a global biopharmaceutical company that is helping healthcare providers turn incurable cancers into chronic, manageable diseases, as well as manage serious inflammatory conditions through innovative therapies. This dedication to medical progress goes hand-in-hand with our industry-leading patient support and access programs. Together, these aspects form the core of our commitment to patients worldwide. For more information, visit www.celgene.com.

Daichi Sankyo, Inc.
Exhibit # 25

Daichi Sankyo, Inc. draws on a rich heritage of innovations, integrity and accountability. While success of our medicine speaks for itself, our corporate mission defines our vision and purpose: To enrich quality of life around the world through the development of innovative pharmaceuticals. Injectafer is used to treat adults with iron deficiency anemia (IDA): When oral iron treatments haven’t worked, or side effects from oral iron couldn’t be tolerated, and for adults with non-dialysis-dependent chronic kidney disease.

enterade® - Entrinsic Health Solutions, Inc.
Exhibit # 36

enterade® is an amino acid-based, glucose free, medical food/beverage that is lightly sweetened with stevia leaf extract. enterade® provides select amino acids and electrolytes (sodium and potassium) – the nutrients needed to rebuild and protect the GI tract and deliver total body hydration for patients undergoing treatment for cancer.

Genentech
Exhibit # 6 & 7

For more than 40 years, we’ve been following the science, seeking solutions to unmet medical needs. As a proud member of the Roche Group, we make medicines to treat patients with serious medical conditions.

Genoptix
Exhibit # 13

For almost 20 years, Genoptix has provided the vital insights Cancer Care Teams need to achieve the best possible outcome for each and every patient. Our testing services combine data from both pathology expertise and next-generation testing into one tailored report, enabling confident decisions in optimizing precision medicine. With over 1.7 million patients and counting, Genoptix sets a higher standard of quality, from science to service. Because what matters most is delivering the right answer, right now.

Patient Advocacy Pavilion Sponsor
**Gilead Sciences, Inc.**

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company’s mission is to advance the care of patients suffering from life-threatening diseases worldwide. Gilead has operations in more than 30 countries worldwide, with headquarters in Foster City, California.

**Harborside**

Harborside is the publisher of JNCCN—Journal of the National Comprehensive Cancer Network, covering the entire spectrum of cancer care; The ASCO Post, a newspaper featuring coverage of important issues in the field of oncology; JOP, providing research to inform the delivery of efficient, quality cancer care; and Journal of the JADPRO, a clinical journal for the NP, CNS and PAs. Harborside provides advertising services for Journal of Clinical Oncology, Journal of Global Oncology, JCO Clinical Cancer Information, and JCO Precision Oncology.

**Helsinn Therapeutics**

Helsinn is a privately owned pharmaceutical group headquartered in Lugano, Switzerland, with operating subsidiaries in Ireland, the U.S., and a representative office in China. Helsinn is one of the world’s leading supportive cancer care companies. Our portfolio of products combines therapies we license and therapies developed at Helsinn. www.helsinn.com

**Incyte Corporation**

Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit the Company’s web site at www.incyte.com. Follow @Incyte on Twitter at https://twitter.com/incyte.

**Janssen Oncology**

At Janssen Oncology, we’re shaping the future of cancer treatment. And in the process, we’re striving to change expectations of what a cancer diagnosis means. Our purpose is driven by an urgency and commitment to bringing transformational cancer solutions to the people who need them. Passionate about our work, we are driven by the personal connection many of us share with the disease. With our partners, we focus on delivering solutions that make a positive impact on human health. We are part of Janssen Biotech, Inc., and the Janssen Pharmaceutical Companies of Johnson & Johnson. For more information, visit www.janssen.com.

**Jazz Pharmaceuticals, Inc.**

Jazz Pharmaceuticals plc is an international biopharmaceutical company focused on improving patients’ lives by identifying, developing and commercializing meaningful products that address unmet medical needs.

**Karyopharm Therapeutics Inc.**

Karyopharm Therapeutics Inc. is a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport and related targets for the treatment of cancer and other major diseases.

**Kite, a Gilead Company**

Kite, a Gilead Company, is a biopharmaceutical company based in Santa Monica, California. Kite is engaged in the development of innovative cancer immunotherapies. The company is focused on chimeric antigen receptor and T cell receptor engineered cell therapies. For more information on Kite, please visit www.kitepharma.com.

**Merck & Co., Inc.**

Merck (known as MSD outside the US and Canada) is a global health care leader working to help the world be well. Through our prescription medicines, vaccines, biologic therapies, and animal health products, we work to deliver innovative health solutions and are committed to increasing access to health care.

**Novartis**

At Novartis, our mission is to discover new ways to improve and extend people’s lives. We use science-based innovation to address some of society’s most challenging health care issues. We discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible.

As a leader in oncology, Novartis offers a portfolio of more than 20 approved therapies and approximately 30 compounds in development. www.novartis.com

**Pharmacyclics, LLC**

Pharmacyclics, LLC, an AbbVie Company is focused on developing and commercializing innovative small-molecule medications for the treatment of cancer and immune-mediated diseases. Our mission is to provide treatment options that help our patients rediscover the magic of normal.

**Sandoz, a Novartis Division**

Sandoz, a Novartis division, is a global leader in generic pharmaceuticals and biosimilars. Our purpose is to discover new ways to improve and extend people’s lives. We pioneer novel approaches to drive access to medicine. Our portfolio comprises over 1000 molecules and our products reach more than 500 million patients.
About Our Exhibitors

Seattle Genetics
Exhibit # 14
Seattle Genetics is an emerging multi-product, global biotechnology company that develops and commercializes transformative therapies targeting cancer to make a meaningful difference in people’s lives. ADCETRIS® (brentuximab vedotin) utilizes the company’s industry-leading antibody-drug conjugate (ADC) technology and is currently approved for the treatment of multiple CD30-expressing lymphomas. Beyond ADCETRIS, the company has established a pipeline of novel targeted therapies at various stages of clinical testing, including three in ongoing or planned pivotal trials for solid tumors. In addition, we are leveraging our expertise in empowered antibodies to build a portfolio of proprietary immuno-oncology agents in clinical trials targeting hematologic malignancies and solid tumors.

Servier Pharmaceuticals, Inc.
Exhibit # 30
At Servier, we aim to make a difference in the lives of people living with cancer.

Spectrum Pharmaceuticals, Inc.
Exhibit # 4
Spectrum Pharmaceuticals is a leading biotechnology company focused on acquiring, developing, and commercializing drug products, with a primary focus in Hematology and Oncology. Spectrum currently markets six hematology/oncology drugs, and has an advanced stage pipeline that has the potential to transform the Company. More information available at www.sppirx.com.

Takeda Oncology
Exhibit # 33
At Takeda Oncology, the oncology business unit brand of Takeda Pharmaceutical Company Limited, we endeavor to deliver novel medicines to patients with cancer worldwide through our commitment to science, breakthrough innovation and passion for improving the lives of patients. This singular focus drives our aspirations to discover, develop and deliver breakthrough oncology therapies. By concentrating the power of leading scientific minds and the vast resources of a global pharmaceutical company, we are finding innovative ways to improve the treatment of cancer.

Verastem Oncology
Exhibit # 29
Verastem, Inc. (NASDAQ:VSTM) is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. Verastem is currently developing duvelisib, a dual inhibitor of PI3K-delta and PI3K-gamma, which has successfully met its primary endpoint in a Phase 2 study in indolent non-Hodgkin lymphoma (iNHL) and a Phase 3 clinical trial in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).

SPECTRUM IS COMMITTED TO THE FIGHT AGAINST CANCER

At Spectrum Pharmaceuticals, we are committed to excellence and strive to make a difference in the lives of patients every day. We are a biotechnology Company with fully integrated commercial and drug development operations, and a focus in oncology and hematology. We are proud to be engaged in the development and commercialization of innovative treatments for cancer patients.

Corporate Office: 11500 South Eastern Ave. • Suite 240 • Henderson, NV 89052
Tel: 702.835.6300 • Fax: 702.260.7405

Research & Development: 157 Technology Drive • Irvine, CA 92618
Tel: 949.788.6700 • Fax: 949.788.6706

www.sppirx.com • NASDAQ: SPPI

Come see us at Booth #4
Important Safety Information

- Treatment with Jakafi can cause thrombocytopenia, anemia and neutropenia, which are each dose-related effects. Perform a pre-treatment complete blood count (CBC) and monitor CBCs every 2 to 4 weeks until doses are stabilized, and then as clinically indicated.

- Manage thrombocytopenia by reducing the dose or temporarily interrupting Jakafi. Platelet transfusions may be necessary.

- Patients developing anemia may require blood transfusions and/or dose modifications of Jakafi.

- Severe neutropenia (ANC <0.5 × 10⁹/L) was generally reversible by withholding Jakafi until recovery.

- Serious bacterial, mycobacterial, fungal and viral infections have occurred. Delay starting Jakafi until active serious infections have resolved. Observe patients receiving Jakafi for signs and symptoms of infection and manage promptly.

- Tuberculosis (TB) infection has been reported. Observe patients taking Jakafi for signs and symptoms of active TB and manage promptly. Prior to initiating Jakafi, evaluate patients for TB risk factors and test those at higher risk for latent infection. Consult a physician with expertise in the treatment of TB before starting Jakafi in patients with evidence of active or latent TB. Continuation of Jakafi during treatment of active TB should be based on the overall risk-benefit determination.

- Progressive multifocal leukoencephalopathy (PML) has occurred with Jakafi treatment. If PML is suspected, stop Jakafi and evaluate.

- Advise patients about early signs and symptoms of herpes zoster and to seek early treatment.

PV, polycythemia vera.

MF, myelofibrosis.
Visit the Incyte booth to learn about intervening with Jakafi, the first and only therapy approved for patients with:

- Polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea
- Intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis

- Increases in hepatitis B viral load with or without associated elevations in alanine aminotransferase and aspartate aminotransferase have been reported in patients with chronic hepatitis B virus (HBV) infections. Monitor and treat patients with chronic HBV infection according to clinical guidelines.
- When discontinuing Jakafi, myeloproliferative neoplasm-related symptoms may return within one week. After discontinuation, some patients with myelofibrosis have experienced fever, respiratory distress, hypotension, DIC, or multi-organ failure. If any of these occur after discontinuation or while tapering Jakafi, evaluate and treat any intercurrent illness and consider restarting or increasing the dose of Jakafi. Instruct patients not to interrupt or discontinue Jakafi without consulting their physician. When discontinuing or interrupting Jakafi for reasons other than thrombocytopenia or neutropenia, consider gradual tapering rather than abrupt discontinuation.
- Non-melanoma skin cancers including basal cell, squamous cell, and Merkel cell carcinoma have occurred. Perform periodic skin examinations.
- Treatment with Jakafi has been associated with increases in total cholesterol, low-density lipoprotein cholesterol, and triglycerides. Assess lipid parameters 8-12 weeks after initiating Jakafi. Monitor and treat according to clinical guidelines for the management of hyperlipidemia.

- The three most frequent non-hematologic adverse reactions (incidence >10%) were bruising, dizziness, and headache.
- A dose modification is recommended when administering Jakafi with strong CYP3A4 inhibitors or fluconazole or in patients with renal or hepatic impairment. Patients should be closely monitored and the dose titrated based on safety and efficacy.
- Use of Jakafi during pregnancy is not recommended and should only be used if the potential benefit justifies the potential risk to the fetus. Women taking Jakafi should not breastfeed during treatment and for two weeks after the final dose.

Please see Brief Summary of Full Prescribing Information for Jakafi on the following pages.
**Jakafi® (ruxolitinib) tablets**

**BRIEF SUMMARY:** For Full Prescribing Information, see package insert.

**CONTRAINDICATIONS:** None.

**WARNINGS AND PRECAUTIONS**

**Thrombocytopenia, Anemia and Neutropenia** Treatment with Jakafi can cause thrombocytopenia, anemia, and neutropenia. [see Dosage and Administration (2.1) in Full Prescribing Information]. Manage thrombocytopenia by reducing the dose or temporarily interrupting Jakafi. Platelet transfusions may be necessary [see Dosage and Administration (2.1.1) and Adverse Reactions (6.1) in Full Prescribing Information]. Patients developing anemia may require blood transfusions and/or dose modifications of Jakafi. Severe neutropenia (ANC less than 0.5 X 10^9/L) was generally reversible by withholding Jakafi until recovery [see Adverse Reactions (6.1) in Full Prescribing Information]. Perform a pre-treatment complete blood count (CBC) and monitor CBCs every 2 to 4 weeks until doses are stabilized, and then as clinically indicated [see Dosage and Administration (2.1.1) and Adverse Reactions (6.1) in Full Prescribing Information].

**Risk of Infection**

Serious bacterial, mycobacterial, fungal, and viral infections have occurred. Delay starting therapy with Jakafi until active serious infections have resolved. Observe patients receiving Jakafi for signs and symptoms of infection and manage promptly. Tuberculosis. Tuberculosis infection has been reported in patients receiving Jakafi. Observe patients receiving Jakafi for signs and symptoms of active tuberculosis and manage promptly. Prior to initiating Jakafi, patients should be evaluated for tuberculosis risk factors, and those at higher risk should be tested for latent infection. Risk factors include, but are not limited to, prior residence in or travel to countries with a high prevalence of tuberculosis, close contact with a person with active tuberculosis, and a history of active or latent tuberculosis where an adequate course of treatment cannot be confirmed. For patients with evidence of active or latent tuberculosis, consult a physician with expertise in the treatment of tuberculosis before starting Jakafi. The decision to continue Jakafi during treatment of active tuberculosis should be based on the overall risk-benefit determination.

**Progressive Multifocal Leukoencephalopathy** Progressive multifocal leukoencephalopathy (PML) has occurred with Jakafi treatment. If PML is suspected, stop Jakafi and evaluate.

**Hepatic Toxicity** Advise patients about early signs and symptoms of hepatic toxicity and to seek treatment as early as possible if suspected [see Adverse Reactions (6.1) in Full Prescribing Information]. Hepatocellular Hepatitis B viral load (HBV-DNA level) increases, with or without associated elevations in alanine aminotransferase and aspartate aminotransferase, have been reported in patients with chronic HBV infections taking Jakafi. The effect of Jakafi on viral replication in patients with chronic HBV infection is unknown. Patients with chronic HBV infection should be treated and monitored according to clinical guidelines.

**Symptom Exacerbation Following Interruption or Discontinuation of Treatment with Jakafi** Following discontinuation of Jakafi, symptoms from myeloproliferative neoplasms may return to pretreatment levels over a period of approximately one week. Some patients with MF have experienced one or more of the following adverse events after discontinuing Jakafi: fever, respiratory distress, hypotension, DIC, or multi-organ failure. If one or more of these occur after discontinuation of, or while tapering the dose of Jakafi, evaluate for and treat any intercurrent illness and consider restarting or increasing the dose of Jakafi. Instruct patients not to interrupt or discontinue Jakafi therapy without consulting their physician. When discontinuing or interrupting therapy with Jakafi for reasons other than thrombocytopenia or neutropenia [see Dosage and Administration (2.5) in Full Prescribing Information], consider tapering the dose of Jakafi gradually rather than discontinuing abruptly.

**Non-Melanoma Skin Cancer** Non-melanoma skin cancers including basal cell, squamous cell, and Merkel cell carcinoma have occurred in patients treated with Jakafi. Perform periodic skin examinations. 

**Lipid Changes** 

Table 1: Myelofibrosis: Adverse Reactions Occurring in Patients on Jakafi in the Double-blind, Placebo-controlled Study During Randomized Treatment

<table>
<thead>
<tr>
<th>Adverse Reactions</th>
<th>All Grades (%)</th>
<th>Grade 3 (%)</th>
<th>Grade 4 (%)</th>
<th>All Grades (%)</th>
<th>Grade 3 (%)</th>
<th>Grade 4 (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bruising*</td>
<td>23</td>
<td>&lt;1</td>
<td>0</td>
<td>15</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Dizziness*</td>
<td>18</td>
<td>&lt;1</td>
<td>0</td>
<td>7</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Headache</td>
<td>15</td>
<td>0</td>
<td>0</td>
<td>5</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Urinary Tract Infections*</td>
<td>9</td>
<td>0</td>
<td>0</td>
<td>5</td>
<td>&lt;1</td>
<td>0</td>
</tr>
<tr>
<td>Weight Gain</td>
<td>7</td>
<td>&lt;1</td>
<td>0</td>
<td>1</td>
<td>&lt;1</td>
<td>0</td>
</tr>
<tr>
<td>Flatulence</td>
<td>5</td>
<td>0</td>
<td>&lt;1</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Herpes Zoster†</td>
<td>2</td>
<td>0</td>
<td>&lt;1</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

* National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), version 3.0

| Concomitant administration of Jakafi with strong CYP3A4 inhibitors increases ruxolitinib exposure [see Warnings and Precautions (5.2) in Full Prescribing Information]. Increased exposure may increase the risk of exposure-related adverse reactions. Avoid the concomitant use of Jakafi with fluconazole (CYP3A4 inhibitor). Flucytosine (CYP3A4 inducer) may increase the exposure of ruxolitinib, but since few patients were treated for multiple cycles, tolerability with continued use was not observed, but since few patients were treated for multiple cycles, tolerability with continued use was not observed, but since few patients were treated for multiple cycles, tolerability with continued use was not observed. The incidence of Grade 2 or worse ruxolitinib-related adverse reactions increased in patients treated with Jakafi and 38% of patients receiving placebo received red blood cell transfusions during randomized treatment. In patients treated with placebo, the median number of units transfused per month was 1.7 in patients treated with Jakafi and 1.2 in placebo treated patients. 

**Thrombocytopenia** In the two Phase 3 clinical studies, median time to onset of first CTCAE Grade 2 or higher anemia was approximately 6 weeks. One patient (<1%) discontinued treatment because of anemia. In patients receiving Jakafi, mean decreases in hemoglobin reached a nadir of approximately 1.5 to 2.0 g/dL below baseline after 8 to 12 weeks of therapy and then gradually recovered to reach a new steady state that was approximately 1.0 g/dL below baseline. This pattern was observed in patients regardless of whether they had received transplants during therapy. In the randomized, placebo-controlled study, 60% of patients treated with Jakafi and 38% of patients receiving placebo received red blood cell transfusions during randomized treatment. In patients receiving placebo or while tapering the dose of Jakafi, evaluate for and treat any intercurrent illness and consider restarting or increasing the dose of Jakafi. 

**Tuberculosis** Risk should be tested for latent infection. Risk factors include, but are not limited to, prior residence in or travel to countries with a high prevalence of tuberculosis, close contact with a person with active tuberculosis, and a history of active or latent tuberculosis where an adequate course of treatment cannot be confirmed.

**Tuberculosis**

- Tuberculosis: an infectious disease caused by the Mycobacterium tuberculosis bacterium.
- Management of tuberculosis: includes treatment with antitubercular drugs, rest, and nutritional support.
- Risk factors: include prior residence in or travel to regions with high tuberculosis prevalence.

**Diabetes**

- Type 2 diabetes: a chronic condition characterized by high blood sugar levels.
- Management: includes lifestyle modifications, medications, and insulin therapy.
- Risk factors: include obesity, physical inactivity, and family history.

**Hypertension**

- A chronic condition characterized by high blood pressure.
- Management: includes lifestyle changes, medications, and monitoring.
- Risk factors: include age, family history, and obesity.

**Chronic Obstructive Pulmonary Disease (COPD)**

- A chronic lung disease characterized by airway obstruction.
- Management: includes bronchodilators, oxygen therapy, and vaccinations.
- Risk factors: include smoking, air pollution, and genetic factors.
Table 3: Polycythemia Vera: Treatment Emergent Adverse Events Occurring in ≥ 8% of Patients on Jakafi in the Open-Label, Active-controlled Study up to Week 32 of Randomized Treatment

<table>
<thead>
<tr>
<th>Adverse Events</th>
<th>Jakafi (N=110)</th>
<th>Best Available Therapy (N=111)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>All Grades (%)</td>
<td>Grade 3-4 (%)</td>
</tr>
<tr>
<td>Headache</td>
<td>16</td>
<td>&lt;1</td>
</tr>
<tr>
<td>Abdominal Pain</td>
<td>15</td>
<td>&lt;1</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>15</td>
<td>0</td>
</tr>
<tr>
<td>Dizziness</td>
<td>15</td>
<td>0</td>
</tr>
<tr>
<td>Fatigue</td>
<td>15</td>
<td>0</td>
</tr>
<tr>
<td>Pruritus</td>
<td>14</td>
<td>&lt;1</td>
</tr>
<tr>
<td>Dyspnea</td>
<td>13</td>
<td>3</td>
</tr>
<tr>
<td>Muscle Spasms</td>
<td>12</td>
<td>&lt;1</td>
</tr>
<tr>
<td>Nasopharyngitis</td>
<td>9</td>
<td>0</td>
</tr>
<tr>
<td>Constipation</td>
<td>8</td>
<td>0</td>
</tr>
<tr>
<td>Cough</td>
<td>8</td>
<td>0</td>
</tr>
<tr>
<td>Edema</td>
<td>8</td>
<td>0</td>
</tr>
<tr>
<td>Arthralgia</td>
<td>7</td>
<td>0</td>
</tr>
<tr>
<td>Asthenia</td>
<td>7</td>
<td>0</td>
</tr>
<tr>
<td>Epistaxis</td>
<td>6</td>
<td>0</td>
</tr>
<tr>
<td>Herpes Zoster</td>
<td>6</td>
<td>&lt;1</td>
</tr>
<tr>
<td>Nausea</td>
<td>6</td>
<td>0</td>
</tr>
</tbody>
</table>

* National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), version 3.0
* Includes abdominal pain, abdominal pain lower, and abdominal pain upper
* Includes dizziness and vertigo
* Includes dyspnea and dyspnea exertional
* Includes edema and peripheral edema
* Includes herpes zoster and post-herpetic neuralgia

Table 4: Polycythemia Vera: Selected Laboratory Abnormalities in the Open-Label, Active-controlled Study up to Week 32 of Randomized Treatment

<table>
<thead>
<tr>
<th>Laboratory Parameter</th>
<th>Jakafi (N=110)</th>
<th>Best Available Therapy (N=111)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>All Grades (%)</td>
<td>Grade 3 (%)</td>
</tr>
<tr>
<td>Hematology</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anemia</td>
<td>72</td>
<td>&lt;1</td>
</tr>
<tr>
<td>Thrombocytopenia</td>
<td>27</td>
<td>5</td>
</tr>
<tr>
<td>Neutropenia</td>
<td>3</td>
<td>0</td>
</tr>
<tr>
<td>Chemistry</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypercholesterolemia</td>
<td>35</td>
<td>0</td>
</tr>
<tr>
<td>Elevated ALT</td>
<td>25</td>
<td>&lt;1</td>
</tr>
<tr>
<td>Elevated AST</td>
<td>23</td>
<td>0</td>
</tr>
<tr>
<td>Hypertriglyceridemia</td>
<td>15</td>
<td>0</td>
</tr>
</tbody>
</table>

* Presented values are worst Grade values regardless of baseline
* National Cancer Institute Common Terminology Criteria for Adverse Events, version 3.0

**DRUG INTERACTIONS**

Fluconazole: Concurrent administration of Jakafi with fluconazole doses greater than 200 mg daily may increase ruxolitinib exposure due to inhibition of both the CYP3A4 and CYP2C9 metabolic pathways [see Clinical Pharmacology (12.3) in Full Prescribing Information]. Increased exposure may increase the risk of exposure-related adverse reactions. Avoid the concurrent use of Jakafi with fluconazole doses of greater than 200 mg daily [see Dosage and Administration (2.3) in Full Prescribing Information].

Strong CYP3A4 inhibitors: Concurrent administration of Jakafi with strong CYP3A4 inhibitors increases ruxolitinib exposure [see Clinical Pharmacology (12.3) in Full Prescribing Information]. Increased exposure may increase the risk of exposure-related adverse reactions. Consider dose reduction when administering Jakafi with strong CYP3A4 inhibitors [see Dosage and Administration (2.3) in Full Prescribing Information].

**Strong CYP3A4 inducers**

Concomitant administration of Jakafi with strong CYP3A4 inducers may decrease ruxolitinib exposure [see Clinical Pharmacology (12.3) in Full Prescribing Information]. No dose adjustment is recommended; however, monitor patients frequently and adjust the Jakafi dose based on safety and efficacy [see Clinical Pharmacology (12.3) in Full Prescribing Information].

**USE IN SPECIFIC POPULATIONS**

**Pregnancy:** Risk Summary

When pregnant rats and rabbits were administered ruxolitinib during the period of organogenesis adverse developmental outcomes occurred at doses associated with maternal toxicity (see Data). There are no adequate and well-controlled studies in pregnant women to inform drug-associated risks. The background risk of major birth defects and miscarriage for the indicated populations is unknown. Adverse outcomes in pregnancy occur regardless of the health of the mother or the use of medications. The background risk in the U.S. general population of major birth defects is 2% to 4% and miscarriage is 15% to 20% of clinically recognized pregnancies. Data: Animal Data Ruxolitinib was administered orally to pregnant rats or rabbits during the period of organogenesis, at doses of 15, 30 or 60 mg/kg/day in rats and 10, 30, or 60 mg/kg/day in rabbits. There were no treatment-related malformations. Adverse developmental outcomes, such as decreases of approximately 9% in fetal weights were noted in rats at the highest and maternally toxic dose of 60 mg/kg/day. This dose results in an exposure (AUC) that is approximately 2 times the clinical exposure at the maximum recommended dose of 25 mg twice daily. In rabbits, lower fetal weights of approximately 8% and increased late resorptions were noted at the highest and maternally toxic dose of 60 mg/kg/day. This dose is approximately 7% the clinical exposure at the maximum recommended dose. In a pre- and post-natal development study in rats, pregnant animals were dosed with ruxolitinib from implantation through lactation at doses up to 30 mg/kg/day. There were no drug-related adverse findings in pups for fertility indices or for maternal or embryofetal survival, growth and development parameters at the highest dose evaluated (34% the clinical exposure at the maximum recommended dose of 25 mg twice daily).

**Lactation:** Risk Summary

No data are available regarding the presence of ruxolitinib in human milk, the effects on the breast fed infant, or the effects on milk production. Ruxolitinib and/or its metabolites were present in the milk of lactating rats (see Data). Because many drugs are present in human milk and because of the potential for thrombocytopenia and anemia shown for Jakafi in human studies, discontinue breastfeeding during treatment with Jakafi and for two weeks after the final dose. Data: Animal Data Lactating rats were administered a single dose of [14C]-labeled ruxolitinib (30 mg/kg) on postnatal Day 10, after which plasma and milk samples were collected for up to 24 hours. The AUC for total radioactivity in milk was approximately 13-fold the maternal plasma AUC. Additional analysis showed the presence of ruxolitinib and several of its metabolites in milk, all at levels higher than those in maternal plasma.

**Pediatric Use**

The safety and effectiveness of Jakafi in pediatric patients have not been established. Jakafi was evaluated in a single-arm, dose-escalation study (NCT01164163) in 27 pediatric patients with relapsed or refractory solid tumors (Cohort A) and 20 with leukemias or myeloproliferative neoplasms (Cohort B). The patients had a median age of 14 years (range: 2 to 21 years) and included 18 children (age 2 to <12 years), and 14 adolescents (age 12 to <17 years). The dose levels tested were 15, 21, 29, 39, and 50 mg/m2 twice daily in 28-day cycles with up to 6 patients per dose group. Overall, 38 (81%) patients were treated with no more than a single cycle of Jakafi, while 3, 1, 2, and 3 patients received 2, 3, 4, and 5 more cycles, respectively. A protocol defined maximal tolerated dose was not observed, but since few patients were treated for multiple cycles, tolerability with continued use was not assessed adequately to establish a recommended Phase 2 dose. The safety profile in children was similar to that seen in adults. **Geriatric Use**

Of the total number of patients with MF in clinical studies with Jakafi, 52% were 65 years and older, while 15% were 75 years and older. No overall differences in safety or effectiveness of Jakafi were observed between these patients and younger patients.

**Renal Impairment**

Reduce the Jakafi dosage when administering Jakafi to patients with MF and moderate (Clcr 30 mL/min to 59 mL/min as estimated using Cockcroft-Gault or severe renal impairment (Clcr 15 mL/min to 29 mL/min) with a platelet count between 50 x 10^9/L and 150 x 10^9/L [see Dosage and Administration (2.4) and Clinical Pharmacology (12.3) in Full Prescribing Information]. Reduce the Jakafi dosage for patients with PV and moderate (Clcr 30 to 59 mL/min) or severe renal impairment (Clcr 15 to 29 mL/min) [see Dosage and Administration (2.4) and Clinical Pharmacology (12.3) in Full Prescribing Information]. Reduce the Jakafi dosage for all patients with ESRD on dialysis [see Dosage and Administration (2.4) and Clinical Pharmacology (12.3) in Full Prescribing Information].

**Hepatic Impairment**

Reduce the Jakafi dosage when administering Jakafi to patients with MF and any degree of hepatic impairment (Child-Pugh Class A, B and C) and with a platelet count between 50 x 10^9/L and 150 x 10^9/L [see Dosage and Administration (2.4) and Clinical Pharmacology (12.3) in Full Prescribing Information]. Reduce the Jakafi dosage for patients with PV and hepatic impairment (Child-Pugh Class B and C) [see Dosage and Administration (2.4) and Clinical Pharmacology (12.3) in Full Prescribing Information].

**OVERDOSAGE**

There is no known antidote for overdoses with Jakafi. Single doses up to 200 mg have been given with acceptable acute tolerability. Higher than recommended repeat doses are associated with increased myelosuppression including leukopenia, anemia and thrombocytopenia. Appropriate supportive treatment should be given. Hemodialysis is not expected to enhance the elimination of Jakafi.

Jakafi is a registered trademark of Incyte. All rights reserved. U.S. Patent Nos. 7582857; 8415362; 8722689; 8824841; 8829013; 9079112 © 2011-2018 Incyte Corporation. All rights reserved. Revised: December 2017. RUX-2402a
The cost of cancer care continues to rise and patients with cancer and their caregivers often struggle to pay for therapy. As a response to these ongoing challenges, help is available through the NCCN Reimbursement Resource App; users are able to search for available resources and payment assistance programs.

Search by:
- Cancer Type or Supportive Care Indication
- Drug Name
- Reimbursement or Assistance Program

NCCN.org/reimbursement
Patient Advocates

Cancer Hope Network
Kiosk # A1
Cancer Hope Network provides free one-on-one emotional support to adult cancer patients and their loved ones. Each of CHN’s 400+ volunteers is at least one year post-treatment or successfully undergoing maintenance therapies. They have faced more than 80 cancer types and speak 15 languages. Our volunteers offer support from diagnosis, through treatment and into recovery. Cancer Hope Network serves cancer patients in the United States and Canada.

CancerCare®
Kiosk # A2
CancerCare® is the leading national organization dedicated to providing free, professional support services including counseling, support groups, educational workshops, publications and financial assistance to anyone affected by cancer. All CancerCare services are provided by oncology social workers and world-leading cancer experts.

CLL Society
Kiosk # A3
The CLL Society is a physician-curated, patient-centric, nonprofit providing education, research and support for patients with chronic lymphocytic leukemia. We help by informing and supporting CLL patients through our free toolkits, website, educational programs, and nationwide patient/caregiver support groups. Visit our website at www.cllsociety.org and booth to order our free educational toolkit.

Lymphoma Research Foundation
Kiosk # A4
The Lymphoma Research Foundation (LRF) is the nation’s largest non-profit organization devoted to funding innovative lymphoma research and providing people with lymphoma and healthcare professionals with up-to-date education about this type of cancer. The LRF mission is to eradicate lymphoma and serve those touched by this disease. LRF is dedicated to identifying a cure through an aggressively funded research program and to helping members of the lymphoma community by providing comprehensive, disease-specific programs and services.

Myeloma Crowd
Kiosk # A5
Myeloma Crowd would like to introduce their new platform, HealthTree. HealthTree is a patient-led community effort where myeloma patients own their data and merge it into a collective network with other myeloma patients. As patients enter their data into the HealthTree platform, the system educates them on personally relevant treatment options and clinical trials, they can discuss with their doctors. Come learn more today!

New Tang Dynasty TV
Kiosk # A6
NTD is a 501c(3) TV broadcaster founded in 2001 by Chinese Americans in response to the lack of independent media that broadcast in Chinese language in the U.S. Headquartered in New York City, NTD is committed to helping new immigrants integrate into American society to access health information.

SHARE
Kiosk # A7
SHARE is a national nonprofit that supports, educates and empowers women affected by breast or ovarian cancer, with a special focus on medically underserved communities. SHARE meets women wherever they are with the insight of peers who have been there too, creating a nationwide community where no one feels alone. Its free services include support groups, educational tools, expert-led webinars and presentations, a national helpline, online communities, advocacy opportunities, and survivor-patient navigation.

The Leukemia & Lymphoma Society
Kiosk # A8
The mission of The Leukemia & Lymphoma Society (LLS) is: Cure leukemia, lymphoma, Hodgkin’s disease and myeloma, and improve the quality of life of patients and their families. LLS exists to find cures and ensure access to treatments for blood cancer patients. We are the voice for all blood cancer patients and we work to ensure access to treatments for all blood cancer patients.

Roswell Park Comprehensive Cancer Center is seeking two board-certified hematologists/medical oncologists with clinical/translational research interests to lead robust and cutting-edge programs in our Myeloma and Lymphoma Sections.

Interested applicants may inquire by email to Angela.Gunther@RoswellPark.org
For all job openings, visit: RoswellPark.org/Careers

IMAGINE
WORKING AMONG 3,000 SCIENTIFIC, ACADEMIC, AND MEDICAL MINDS
Joined Together

to eliminate cancer’s grip on humanity by unlocking its secrets through personalized approaches and unleashing the healing power of hope.
With CancerCare®, the difference comes from:

- Professional oncology social workers
- Counseling and support groups
- Financial assistance
- Resources and education

Access our services by telephone, face-to-face and online.

CancerCare provides free, professional support services for people affected by cancer, including patients, survivors and caregivers.

275 SEVENTH AVENUE, NEW YORK, NY 10001
WWW.CANCERCARE.ORG | 800-813-HOPE (4673)

Nonprofit TV broadcaster
Connection to Asian patients and physicians
Dedication to public health and patient advocacy in the Asian community in US
Multi-language services: Chinese, Korean, Vietnamese, English

Visit our booth or email us at: health@ntdtv.com
NCCN Apps for the Oncology Community

Virtual Library of NCCN Guidelines®
PRICE: Free
PLATFORMS: iOS and Android™ Smartphone and Tablet

Health care professionals can access the full library of NCCN Guidelines featuring more than 180 algorithms that apply to 97% of cancers in the United States from their mobile devices. Treatment recommendations are available on the go or at point of care, thus improving the quality and effectiveness of care provided to patients with cancer.

NCCN Patient Guides for Cancer
PRICE: Free
PLATFORMS: iOS and Android™ Smartphone and Tablet

Patients, caregivers, patient advocates, and case managers can access the NCCN Guidelines for Patients® and NCCN Quick Guide™ sheets from their mobile device. The app features patient-friendly adaptations of the same clinical practice guidelines their doctors use that include questions to ask their care team, patient-friendly illustrations, and expansive glossaries of terms and acronyms.

NCCN Reimbursement Resource
PRICE: Free
PLATFORMS: iOS and Android™ Smartphone and Tablet

Health care professionals, financial navigators, caregivers, and patients can access the NCCN Reimbursement Resource from their mobile device. Users can search for available reimbursement resources and payment assistance programs by cancer type or supportive care indication, product name, or company/program name.

Visit NCCN.org/apps or download through the app store on your mobile device.
For more than thirty years, Cancer Hope Network Support Volunteers like those pictured above have been providing free one-on-one emotional support to adult cancer patients and their caregivers.

Each of our 400+ Support Volunteers is at least one year post-treatment or successfully undergoing maintenance therapies. They represent more than 80 cancer types and speak 15 languages. They offer encouragement from diagnosis, through treatment and into survivorship.

Our volunteers are trained and coordinated by our social worker-led Patient Services Team who connect people based on diagnosis, treatment they’re undergoing or considering and, of course, other psychosocial issues they may be facing. Our services are always free and always confidential.

For more information or to learn how we can support your patients and their caregivers, top by our table, visit cancerhopenetwork.org or call 877-HOPENET.

CANCERHOPENETWORK.ORG
877-HOPENET
CANCERHOPENETWORK.ORG

The CLL Society is a physician-curated, patient-centric, nonprofit providing education, research and support for patients with chronic lymphocytic leukemia. We help by informing and supporting your CLL patients through our free toolkits, website, educational programs, and nationwide patient/caregiver support groups.

Visit our website at cllsociety.org and booth to order our free educational toolkit.
Just like no two people are exactly the same, neither are their cancers. Each patient’s cancer is fueled by different, unique elements that help cancer cells develop, survive, invade and grow. That’s why researchers and oncologists at The James at Ohio State study the unique genetic makeup of each patient’s cancer. As they discover what drives a patient’s cancer, they develop and deliver the most advanced targeted treatments, leading to better outcomes, faster responses, fewer side effects and more hope. To learn more, visit cancer.osu.edu.

The James
No one understands breast or ovarian cancer like someone who’s had it too.

844.ASK.SHARE

- Trained peer helpline for breast, ovarian, and metastatic breast cancer available in 19 languages
- In-person and video/phone support groups
- Webinars and educational programs
- Outreach to medically-underserved communities
- Online communities
- Clinical trial assistance
- Educational tools
- Workplace wellness
- Survivor-patient navigation

ALWAYS AVAILABLE, ALWAYS FREE
sharecancersupport.org | latina.sharecancersupport.org
FB: @SHARE Cancer Support | @SHARE Latina
TW: @SHAREing
IG: @SHARECancerSupport

NCCN 2019 Annual Congress:
Hematologic Malignancies™

September 27 – 28, 2019
Hilton San Francisco Union Square
San Francisco, CA

NCCN.org/hem
National Comprehensive Cancer Network®
Need a great resource on cancer?

NCCN Guidelines for Patients®
empower you to make informed
decisions at each step of your
cancer journey.

CANCER TREATMENT:
Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
Brain Cancer/Gliomas
Breast Cancer
Noninvasive Breast Cancer
Early-Stage (Stages I and II)
Locally Advanced (Stage III)
Metastatic Breast Cancer
Chronic Lymphocytic Leukemia
Chronic Myeloid Leukemia
Colon Cancer
Esophageal Cancer
Hepatobiliary Cancers
Liver, Gallbladder, and Bile Duct Cancers
Hodgkin Lymphoma
Kidney Cancer
Lung Cancer
Non-Small Cell Lung Cancer
Malignant Pleural Mesothelioma
Melanoma
Multiple Myeloma
Myelodysplastic Syndromes
Myeloproliferative Neoplasms
Non-Hodgkin’s Lymphomas
Diffuse Large B-cell Lymphoma
Follicular Lymphoma
Mantle Cell Lymphoma
Mycosis Fungoides
Peripheral T-cell Lymphoma
Ovarian Cancer
Pancreatic Cancer
Prostate Cancer
Rectal Cancer
Soft Tissue Sarcoma
Stomach Cancer
Thyroid Cancer
Waldenström’s Macroglobulinemia/
Lymphoplasmacytic Lymphoma

SUPPORTIVE CARE:
Distress
Nausea and Vomiting

CANCER SCREENING:
Lung Cancer Screening

AGE-RELATED:
Adolescents and Young Adults
(AYAs) with Cancer

TRANSLATIONS:
Kidney Cancer
Chinese
Czech
German
Spanish
Stomach Cancer
Italian

ONLINE
NCCN.org/patients

MOBILE APP
NCCN Patient Guides for Cancer

PRINT
Amazon.com

HELP US MAKE A TRUE IMPACT IN THE LIVES OF PEOPLE LIVING WITH CANCER
DONATE NOW!
NCCNFoundation.org/Donate
Visit us at our booth to learn more

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.FDA.gov/medwatch or call 1-800-FDA-1088.